Aditi R Saxena

5PUBLICATIONS
5CO-AUTHORS
Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 20, 2025
Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.

Clare Buckeridge, Sonia Cobain, Harold E Bays

|May 16, 2024
Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.

Clare Buckeridge, Nikolaos Tsamandouras, Santos Carvajal-Gonzalez

|Jun 13, 2023
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.

Aditi R Saxena, Juan P Frias, Donal N Gorman

|Dec 14, 2022
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes.

Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi

|Jun 15, 2021
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.

Aditi R Saxena, Donal N Gorman, Ryan M Esquejo

Pageof 1

Frequent Collaborators

2 joint publications

Albert M Kim

2 joint publications

Clare Buckeridge

1 joint publications

Donal N Gorman

1 joint publications

David A Griffith